News Summary

Retro Biosciences, a biotech startup based in San Francisco and backed by OpenAI CEO Sam Altman, is raising a $1 billion Series A funding round. The company’s mission is to extend human lifespan by a decade, building on an initial $180 million seed round also funded by Altman. Retro Biosciences plans to conduct trials for drugs targeting age-related diseases, including Alzheimer’s, leveraging AI to transform regular cells into stem cells. This initiative places Retro Biosciences alongside other major longevity-focused efforts like Altos Labs and Unity Biotechnology.